This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (81)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neonatology and Infant Care  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Adriana Moldovan Costei, MD; Eran Kozer, MD; Tommy Ho, MD, FRCPC; Shinya Ito, MD; Gideon Koren, MD, FRCPC

Arch Pediatr Adolesc Med. 2002;156:1129-1132.

Background  Paroxetine hydrochloride is commonly used for maternal depression, panic disorder, and obsessive-compulsive disorder. The drug readily crosses the human placenta. Although it does not appear to increase teratogenic risk, there have been case reports of neonatal withdrawal. Symptoms were described soon after birth and lasted up to 1 month.

Objective  To investigate whether there is a clinically important discontinuation syndrome in neonates exposed to paroxetine in utero.

Methods  Prospective, controlled cohort study.

Patients  Fifty-five pregnant women counseled prospectively by the Motherisk program in Toronto, Ontario, regarding third-trimester exposure to paroxetine and their infants were included in the study group. Pregnant women who discontinued paroxetine before the third trimester or those receiving other drugs known to cause withdrawal-type symptoms, such as opioids or benzodiazepines, were excluded. A comparison group of 27 women using paroxetine during the first or second trimester and 27 women using nonteratogenic drugs were matched for maternal age, gravity, parity, social drug use, and nonteratogenic drug use.

Results  Of the 55 neonates exposed to paroxetine in late gestation, 12 had complications necessitating intensive treatment and prolonged hospitalization. The most prevalent clinical picture was respiratory distress (n = 9), followed by hypoglycemia (n = 2), and jaundice (n = 1). The symptoms disappeared within 1 to 2 weeks. In the comparison group, only 3 infants experienced complications (P = .03). In logistic regression, only third-trimester exposure to paroxetine was associated with neonatal distress (odds ratio, 9.53; 95% confidence interval, 1.14-79.3).

Conclusion  When used near term, paroxetine is associated with a high rate of neonatal complications, possibly caused by its common discontinuation syndrome.

From the Motherisk program, Division of Clinical Pharmacology/Toxicology, the Hospital for Sick Children, and the University of Toronto, Toronto, Ontario.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Selective Serotonin Reuptake Inhibitor Exposure In Utero and Pregnancy Outcomes
Lund et al.
Arch Pediatr Adolesc Med 2009;163:949-954.
ABSTRACT | FULL TEXT  

Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes
Wisner et al.
Focus 2009;7:374-384.
ABSTRACT | FULL TEXT  

Clinical Management Guidelines for Obstetrician-Gynecologists Use of Psychiatric Medications During Pregnancy and Lactation
ACOG Practice Bulletin
Focus 2009;7:385-400.
ABSTRACT | FULL TEXT  

Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes
Wisner et al.
Am. J. Psychiatry 2009;166:557-566.
ABSTRACT | FULL TEXT  

Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension
Toh et al.
Am. J. Psychiatry 2009;166:320-328.
ABSTRACT | FULL TEXT  

Effects of Antenatal Depression and Antidepressant Treatment on Gestational Age at Birth and Risk of Preterm Birth
Suri et al.
Am. J. Psychiatry 2007;164:1206-1213.
ABSTRACT | FULL TEXT  

Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates
Ferreira et al.
Pediatrics 2007;119:52-59.
ABSTRACT | FULL TEXT  

Paroxetine Use During Pregnancy: Is it Safe?
Thormahlen
The Annals of Pharmacotherapy 2006;40:1834-1837.
ABSTRACT | FULL TEXT  

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.
Oberlander et al.
Arch Gen Psychiatry 2006;63:898-906.
ABSTRACT | FULL TEXT  

Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn
Chambers et al.
NEJM 2006;354:579-587.
ABSTRACT | FULL TEXT  

Neonatal Abstinence Syndrome After In Utero Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants
Levinson-Castiel et al.
Arch Pediatr Adolesc Med 2006;160:173-176.
ABSTRACT | FULL TEXT  

Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?
Koren et al.
CMAJ 2005;172:1457-1459.
FULL TEXT  

Neonatal Signs After Late In Utero Exposure to Serotonin Reuptake Inhibitors: Literature Review and Implications for Clinical Applications
Moses-Kolko et al.
JAMA 2005;293:2372-2383.
ABSTRACT | FULL TEXT  

Pain Reactivity in 2-Month-Old Infants After Prenatal and Postnatal Selective Serotonin Reuptake Inhibitor Medication Exposure
Oberlander et al.
Pediatrics 2005;115:411-425.
ABSTRACT | FULL TEXT  

Discontinuation Syndrome Following Late Pregnancy Exposure to Antidepressants
Koren
Arch Pediatr Adolesc Med 2004;158:307-308.
FULL TEXT  

Neonate Characteristics After Maternal Use of Antidepressants in Late Pregnancy
Kallen
Arch Pediatr Adolesc Med 2004;158:312-316.
ABSTRACT | FULL TEXT  

Pharmacology Review: Drug Therapy and Breastfeeding: Pharmacokinetics, Risk Factors, and Effects on Milk Production
Hale
NeoReviews 2004;5:e164-e172.
FULL TEXT  

Perinatal Outcome Following Third-Trimester Exposure to Paroxetine: An Alternative Interpretation
Pryse-Phillips et al.
Arch Pediatr Adolesc Med 2003;157:601-601.
FULL TEXT  

Perinatal Complications and Maternal Paroxetine
JWatch Psychiatry 2002;2002:2-2.
FULL TEXT